Literature DB >> 20110184

Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes.

Nilani Jeyaratnaganthan1, Kurt Højlund, Jens Peter Kroustrup, Jens Fromholt Larsen, Mette Bjerre, Klavs Levin, Henning Beck-Nielsen, Susana Frago, A Bassim Hassan, Allan Flyvbjerg, Jan Frystyk.   

Abstract

OBJECTIVE: The extracellular domain of the insulin-like growth factor II/mannose-6-phosphate receptor (IGF-II/M6P-R) is present in the circulation, but its relationship with plasma IGF-II is largely unknown. As IGF-II appears to be nutritionally regulated, we studied the impact of obesity, type 2 diabetes (T2D) and weight loss on circulating levels of IGF-II and its soluble receptor.
METHODS: Twenty-three morbidly obese non-diabetic subjects were studied before and after gastric banding (GB), reducing their BMI from 59.3+/-1.8 to 52.7+/-1.6 kg/m(2). Lean controls (n=10, BMI 24.2+/-0.5 kg/m(2)), moderately obese controls (n=21, BMI 31.8+/-1.0 kg/m(2)) and obese T2D patients (n=20, BMI 32.3+/-0.8 kg/m(2)) were studied before and after a hyperinsulinaemic euglycaemic clamp.
RESULTS: Morbidly obese subjects had elevated IGF-II/M6P-R and IGF-II levels, which both decreased following GB (IGF-II/M6P-R: from 0.97+/-0.038 to 0.87+/-0.030 nmol/l, P=0.001; IGF-II: from 134+/-7 to 125+/-6 nmol/l, P=0.01), as did fasting plasma glucose and insulin (P<0.05). However, the metabolic parameters correlated with neither IGF-II nor IGF-II/M6P-R. Obese diabetics had increased IGF-II/M6P-R as compared with lean and obese controls (0.82+/-0.031 vs. 0.70+/-0.033 vs. 0.74+/-0.026 nmol/l; P<0.03) and levels were unaffected by clamp. In the latter cohort, IGF-II/M6P-R but not IGF-II correlated with HbA1c, and fasting plasma C-peptide, insulin and glucose (0.34<r<0.45; P<0.05). In all subjects, BMI correlated with IGF-II/M6P-R (r=0.57; P<0.001) and IGF-II (r=0.39; P<0.005). IGF-II/M6P-R and IGF-II were not associated.
CONCLUSION: Serum IGF-II/M6P-R is up-regulated in morbid obesity, down-regulated by weight loss and elevated in moderately obese T2D. However, although plasma IGF-II was also reduced following GB, the two peptides were not statistically correlated. No acute effect of insulin was seen. These findings indicate that the IGF-II/M6P-R is nutritionally regulated, independently of IGF-II. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110184     DOI: 10.1016/j.ghir.2009.12.005

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  10 in total

Review 1.  Obesity and Cancer Mechanisms: Cancer Metabolism.

Authors:  Benjamin D Hopkins; Marcus D Goncalves; Lewis C Cantley
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

Review 2.  Targeting the insulin growth factor receptor 1.

Authors:  Fernanda I Arnaldez; Lee J Helman
Journal:  Hematol Oncol Clin North Am       Date:  2012-02-28       Impact factor: 3.722

3.  Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress.

Authors:  T Zheng; T Chen; Y Liu; Y Gao; H Tian
Journal:  J Hum Hypertens       Date:  2014-11-20       Impact factor: 3.012

4.  Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals.

Authors:  Hyeon-Sook Suh; Yungtai Lo; Namjong Choi; Scott Letendre; Sunhee C Lee
Journal:  J Neuroinflammation       Date:  2015-04-15       Impact factor: 8.322

5.  Characterization of IGF-II isoforms in binge eating disorder and its group psychological treatment.

Authors:  Giorgio Tasca; Julien Yockell Lelievre; Qing Qiu; Kerri Ritchie; Julian Little; John Little; Anne Trinneer; Ann Barber; Livia Chyurlia; Hany Bissada; Andreé Gruslin
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

6.  The association of soluble IGF2R and IGF2R gene polymorphism with type 2 diabetes.

Authors:  Suwannee Chanprasertyothin; Wallaya Jongjaroenprasert; Boonsong Ongphiphadhanakul
Journal:  J Diabetes Res       Date:  2015-04-02       Impact factor: 4.011

Review 7.  The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes.

Authors:  Natalie J Haywood; Thomas A Slater; Connor J Matthews; Stephen B Wheatcroft
Journal:  Mol Metab       Date:  2018-10-24       Impact factor: 7.422

Review 8.  The Neglected Insulin: IGF-II, a Metabolic Regulator with Implications for Diabetes, Obesity, and Cancer.

Authors:  Jeff M P Holly; Kalina Biernacka; Claire M Perks
Journal:  Cells       Date:  2019-10-06       Impact factor: 6.600

Review 9.  The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus.

Authors:  Moira S Lewitt; Mairi S Dent; Kerstin Hall
Journal:  J Clin Med       Date:  2014-12-22       Impact factor: 4.241

10.  Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patients.

Authors:  Vita Birzniece; Teresa Lam; Mark McLean; Navneeta Reddy; Haleh Shahidipour; Amy Hayden; Howard Gurney; Glenn Stone; Rikke Hjortebjerg; Jan Frystyk
Journal:  Endocr Connect       Date:  2022-04-29       Impact factor: 3.221

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.